Abstract：
The Malaysian Society of Gastroenterology and Hepatology saw the need for a consensus statement on metabolic dysfunction-associated fatty liver disease (MAFLD). The consensus panel consisted of experts in the field of gastroenterology/hepatology, endocrinology, bariatric surgery, family medicine, and public health. A modified Delphi process was used to prepare the consensus statements. The panel recognized the high and increasing prevalence of the disease and the consequent anticipated increase in liver-related complications and mortality. Cardiovascular disease is the leading cause of mortality in MAFLD patients; therefore, cardiovascular disease risk assessment and management is important. A simple and clear liver assessment and referral pathway was agreed upon, so that patients with more severe MAFLD can be linked to gastroenterology/hepatology care, while patients with less severe MAFLD can remain in primary care or endocrinology, where they are best managed. Lifestyle intervention is the cornerstone in the management of MAFLD. The panel provided a consensus on the use of statin, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, sodium-glucose cotransporter-2 inhibitor, glucagon-like peptide-1 agonist, pioglitazone, vitamin E, and metformin, as well as recommendations on bariatric surgery, screening for gastroesophageal varices and hepatocellular carcinoma, and liver transplantation in MAFLD patients. Increasing the awareness and knowledge of the various stakeholders on MAFLD and incorporating MAFLD into existing noncommunicable disease-related programs and activities are important steps to tackle the disease. These consensus statements will serve as a guide on MAFLD for clinicians and other stakeholders.
摘要：
马来西亚胃肠病学和肝病学会认为有必要就代谢功能障碍相关的脂肪肝疾病（MAFLD）达成共识。共识小组由胃肠病学/肝病学领域的专家组成，内分泌学,减肥手术,家庭医学,和公共卫生。使用改进的Delphi程序来准备共识声明。该小组认识到该疾病的高且不断增加的患病率以及随之而来的肝脏相关并发症和死亡率的预期增加。心血管疾病是MAFLD患者死亡的主要原因；因此，心血管疾病风险评估和管理非常重要。达成了简单明了的肝脏评估和转诊途径，因此，患有更严重MAFLD的患者可以与胃肠病学/肝病学护理联系起来，虽然不太严重的MAFLD患者可以继续在初级保健或内分泌科，他们最好的管理。生活方式干预是MAFLD管理的基石。小组就他汀类药物的使用达成了共识，血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂，钠-葡萄糖协同转运蛋白-2抑制剂，胰高血糖素样肽-1激动剂，吡格列酮,维生素E,还有二甲双胍,以及关于减肥手术的建议，筛查胃食管静脉曲张和肝细胞癌，MAFLD患者的肝移植。提高各利益相关者对MAFLD的认识和了解，并将MAFLD纳入现有的非传染性疾病相关计划和活动，是应对该疾病的重要步骤。这些共识声明将作为临床医生和其他利益相关者的MAFLD指南。
